Andra AP fonden grew its position in Eli Lilly and Company (NYSE:LLY) by 3.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,400 shares of the company’s stock after buying an additional 6,900 shares during the period. Andra AP fonden’s holdings in Eli Lilly and were worth $19,281,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC increased its holdings in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and during the 2nd quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and in the 2nd quarter worth $129,000. Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and in the 2nd quarter worth $148,000. Institutional investors and hedge funds own 76.42% of the company’s stock.
In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 628,588 shares of company stock valued at $53,399,536 in the last quarter. 0.20% of the stock is currently owned by company insiders.
Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.58 on Monday, reaching $86.45. The company had a trading volume of 3,777,100 shares, compared to its average volume of 3,673,659. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market capitalization of $95,189.66, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. Eli Lilly and Company has a 52-week low of $67.22 and a 52-week high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the company earned $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th were given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend was Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.